Neoleukin’s lead program, NL-201, is believed to be the world’s first computationally-designed de novo protein therapeutic.
Neoleukin is a pioneer in de novo protein development, leveraging computational methods to create new therapies.
A committed team, dedicated to building an enduring company in service of the science, patients, employees, and the community.
A broad set of programs spanning multiple indications, including cancer and autoimmune diseases.
Founded on seminal research, as featured in Nature, heralding a new era of custom protein design.